Self-Collection Devices for Pap Test; Public Workshop; Request for Comments, 42557-42559 [2017-19029]

Download as PDF Federal Register / Vol. 82, No. 173 / Friday, September 8, 2017 / Notices Estimated Total Annual Burden Hours: 2,050. Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 330 C Street SW., Washington, DC 20201. Attention Reports Clearance Officer. All requests should be identified by the title of the information collection. Email address: infocollection@acf.hhs.gov. OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Email: OIRA_ SUBMISSION@OMB.EOP.GOV, Attn: Desk Officer for the Administration for Children and Families. Robert Sargis, Reports Clearance Officer. [FR Doc. 2017–19061 Filed 9–7–17; 8:45 am] BILLING CODE 4184–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2017–N–4790] Self-Collection Devices for Pap Test; Public Workshop; Request for Comments AGENCY: Food and Drug Administration, HHS. Notice of public workshop; request for comments. ACTION: The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled ‘‘Self-Collection Devices for Pap Test.’’ The purpose of the public workshop is to obtain feedback about the feasibility, benefits, risks, impact on current standard of care, and least burdensome validation approaches for self-collection devices for cervical samples for the purpose of cervical cancer screening by Pap testing. Comments and suggestions generated through this workshop will guide the development of an appropriate least burdensome regulatory framework for the evaluation of cervical sample selfcollection devices to be used for cervical cancer screening of patients. sradovich on DSK3GMQ082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:18 Sep 07, 2017 Jkt 241001 42557 DATES: Written/Paper Submissions Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Submit written/paper submissions as follows: • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2017–N–4790 for ‘‘Self-Collection Devices for Pap Test.’’ Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// The public workshop will be held on January 11, 2018, from 9 a.m. to 4 p.m. Submit either electronic or written comments on this public workshop by February 14, 2018. ADDRESSES: The public workshop will be held at FDA’s White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993– 0002. Entrance for the public workshop participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to https:// www.fda.gov/AboutFDA/Working atFDA/BuildingsandFacilities/White OakCampusInformation/ ucm241740.htm. See the SUPPLEMENTARY INFORMATION section for registration date and information. You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before February 14, 2018. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of February 14, 2018. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. PO 00000 Frm 00018 Fmt 4703 Sfmt 4703 E:\FR\FM\08SEN1.SGM 08SEN1 42558 Federal Register / Vol. 82, No. 173 / Friday, September 8, 2017 / Notices www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Shyam Kalavar (Rm. 5660, 301–796– 6807, Shyam.Kalavar@fda.hhs.gov) or Cheng Cui (Rm. 5543, 240–402–5028, Cheng.Cui@fda.hhs.gov), Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Silver Spring, MD 20993–0002. SUPPLEMENTARY INFORMATION: sradovich on DSK3GMQ082PROD with NOTICES I. Background Cervical cancer is a disease that results from uncontrolled, or abnormal, growth of cells in the cervix. Cervical cancer is generally considered as a consequence of a long-term infection with human papillomavirus (HPV), especially with high-risk strains such as HPV16 and 18. Through regular screening and early detection, cervical cancer can often be prevented. According to the National Cancer Institute, routine screening with Pap Test (or Pap smear) and HPV Test in the United States has decreased the incidence of cervical cancer, based on an estimated 12,820 new cases and 4,210 deaths (0.7 percent of all cancer deaths) in 2017 (Ref. 1). The standard of care for cervical cancer screening has been wellestablished in the United States over the past several decades. Automated liquidbased Pap Test has largely replaced conventional Pap smear method. Liquid-based cervical specimens can be used for both Pap Test and HPV Test. By using specimen collection devices such as a cervical broom or cervical spatula and brush combination, cervical specimens are collected by healthcare professionals and sent to a Clinical Laboratory Improvement Amendments certified laboratory for processing for Pap Test and HPV Test. The results of these tests are then returned to the ordering clinician who conveys the results to the patient and initiates appropriate treatment. Despite the established standard of care for cervical cancer screening in the United States, gaps in cervical cancer screening exist. Barriers to cervical cancer screening may include limited access to such services in rural areas, socioeconomic status, etc. As a result, in certain populations and geographic areas of the United States, cervical cancer incidence and death rate are still VerDate Sep<11>2014 17:18 Sep 07, 2017 Jkt 241001 high, due in large part to limited access to cervical cancer screening (Refs. 2–3). The role of self-sampling in overcoming these barriers is unclear. Careful evaluation of risks and benefits, and impact to current standard of care is needed to better understand issues concerning how such devices should be dispensed to end users for selfcollection, proper use of the device to ensure patient safety, the collection of adequate samples for testing, the use of these test results in patient care, and the impact on the current regulatory framework. FDA is holding this public workshop to solicit input from stakeholders about the self-collection of cervical specimens for cancer screening, including its feasibility, benefits, risks, current attitudes, and impact on current standard of care. II. Topics for Discussion at the Public Workshop This public workshop will consist of both morning and afternoon sessions. Each session will include brief presentations followed by an interactive panel discussion. The presentations will provide information to outline the goals of the workshop and help promote interactive discussions. Following the presentations, there will be a moderated discussion where speakers and additional panelists will be asked to provide their individual perspectives. The presentations and discussions will focus on several related topics. The morning session will involve scientific considerations, focusing on the current status of cervical cancer screening and the feasibility, benefits, and risks of selfcollection of cervical specimens for Pap Test. The afternoon session will involve validation and regulatory considerations, focusing on the impact of self-collection of cervical samples on the current standard of care and the regulatory environment for supporting self-collection for Pap Test. A detailed agenda will be posted on the following Web site in advance of the workshop: https://www.fda.gov/MedicalDevices/ NewsEvents/WorkshopsConferences/ default.htm. III. Participating in the Public Workshop Registration: To register for the public workshop, please visit FDA’s Medical Devices News & Events—Workshops & Conferences calendar (https:// www.fda.gov/MedicalDevices/News Events/WorkshopsConferences/ default.htm) and select this event from the list of items provided. Please provide complete contact information for each attendee, including name, title, PO 00000 Frm 00019 Fmt 4703 Sfmt 4703 affiliation, address, email, and telephone number. Registration is free and based on space availability, with priority given to early registrants. Persons interested in attending this public workshop must register by January 3, 2018, 4 p.m. Eastern Time. Early registration is recommended because seating is limited; therefore, FDA may limit the number of participants from each organization. Registrants will receive confirmation when they have been accepted. If time and space permit, onsite registration on the day of the public workshop will be provided beginning at 8 a.m. We will let registrants know if registration closes before the day of the public workshop. If you need special accommodations due to a disability, please contact Susan Monahan, 301–796–5661 or email Susan.Monahan@fda.hhs.gov, no later than December 28, 2017. Requests for Oral Presentations: During online registration you may indicate if you wish to present during a public comment session or participate in a specific session, and which topic(s) you wish to address. We will do our best to accommodate requests to make public comments. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and request time for a joint presentation, or submit requests for designated representatives to participate in the focused sessions. Following the close of registration, we will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin, and will select and notify participants prior to the workshop. All requests to make oral presentations must be received by the close of registration on January 3, 2018, 4 p.m. Eastern Time. If selected for presentation, any presentation materials must be emailed to Shyam Kalavar and Cheng Cui (see FOR FURTHER INFORMATION CONTACT) in advance of the workshop. No commercial or promotional material will be permitted to be presented or distributed at the public workshop. Streaming webcast of the public workshop: This public workshop will also be webcast. The webcast link will be available on the registration web page after January 3, 2018. Organizations are requested to register all participants, but to view using one connection per location. If you have never attended a Connect Pro event before, test your connection at https://collaboration.fda.gov/common/ help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program, visit https://www.adobe.com/ E:\FR\FM\08SEN1.SGM 08SEN1 Federal Register / Vol. 82, No. 173 / Friday, September 8, 2017 / Notices go/connectpro_overview. FDA has verified the Web site addresses in this document, as of the date this document publishes in the Federal Register, but Web sites are subject to change over time. Transcripts: Please be advised that as soon as a transcript of the public workshop is available, it will be accessible at https:// www.regulations.gov. It may be viewed at the Dockets Management Staff (see ADDRESSES). A link to the transcript will also be available on the Internet at https://www.fda.gov/MedicalDevices/ NewsEvents/WorkshopsConferences/ default.htm. IV. References The following references are on display in the Dockets Management Staff (see ADDRESSES) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also available electronically at https:// www.regulations.gov. FDA has verified the Web site addresses, as of the date this document publishes in the Federal Register, but Web sites are subject to change over time. 1. National Cancer Institute, ‘‘Cancer Stat Facts: Cervix Uteri Cancer,’’ (https:// seer.cancer.gov/statfacts/html/ cervix.html). 2. Horner, M.J., S.F. Altekruse, Z. Zou, L. Wideroff, et al. ‘‘U.S. Geographic Distribution of Pre-Vaccine Era Cervical Cancer Screening, Incidence, Stage, and Mortality.’’ Cancer Epidemiology, Biomarkers & Prevention. 2011 Jan.; 20(4):591–9. doi: 10.1158/1055–9965. EPI–10–1183. 3. Freeman, H.W.B. ‘‘Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities.’’ Rockville (MD): National Cancer Institute, Center to Reduce Cancer Health Disparities; 2005. Dated: September 1, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. DEPARTMENT OF HEALTH AND HUMAN SERVICES sradovich on DSK3GMQ082PROD with NOTICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the NHLBI Special Emphasis Panel. Jkt 241001 Dated: September 1, 2017. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–19027 Filed 9–7–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; Pancreatic Cancer Detection Consortium (U01). Date: November 3, 2017. Time: 11:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W240, Rockville, MD 20850, (Telephone Conferece Call). Contact Person: Hasan Siddiqui, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W240, Bethesda, MD 20892–9750, 240–276–5122, hasan.siddiqui@ nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Cooperative Agreement To Develop Targeted Agents Used With Systemic Agents Plus Radiotherapy. Date: November 17, 2017. Time: 10:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W640, Rockville, MD 20850, (Telephone Conferece Call). Contact Person: Saejeong J. Kim, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W640, Bethesda, MD 20892–9750, 240–276–7684, saejeong.kim@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: September 1, 2017. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–19026 Filed 9–7–17; 8:45 am] National Cancer Institute; Notice of Closed Meetings BILLING CODE 4164–01–P 17:18 Sep 07, 2017 Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Resources for Clinical Trials. Date: September 20, 2017. Time: 11:00 a.m. to 1:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 6701 Rockledge Drive, Room 7200, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Michael P. Reilly, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7200, Bethesda, MD 20892, 301–827–7975, reillymp@nhlbi.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) National Institutes of Health [FR Doc. 2017–19029 Filed 9–7–17; 8:45 am] VerDate Sep<11>2014 The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. 42559 BILLING CODE 4140–01–P Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which DEPARTMENT OF HEALTH AND HUMAN SERVICES PO 00000 Frm 00020 Fmt 4703 Sfmt 4703 National Institutes of Health Proposed Collection; 30-Day Comment Request; Application To Participate in the National Institutes of Health Technical Assistance Programs: Commercialization Accelerator Program (CAP) AGENCY: National Institutes of Health, HHS. ACTION: E:\FR\FM\08SEN1.SGM Notice. 08SEN1

Agencies

[Federal Register Volume 82, Number 173 (Friday, September 8, 2017)]
[Notices]
[Pages 42557-42559]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19029]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-4790]


Self-Collection Devices for Pap Test; Public Workshop; Request 
for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is 
announcing the following public workshop entitled ``Self-Collection 
Devices for Pap Test.'' The purpose of the public workshop is to obtain 
feedback about the feasibility, benefits, risks, impact on current 
standard of care, and least burdensome validation approaches for self-
collection devices for cervical samples for the purpose of cervical 
cancer screening by Pap testing. Comments and suggestions generated 
through this workshop will guide the development of an appropriate 
least burdensome regulatory framework for the evaluation of cervical 
sample self-collection devices to be used for cervical cancer screening 
of patients.

DATES: The public workshop will be held on January 11, 2018, from 9 
a.m. to 4 p.m. Submit either electronic or written comments on this 
public workshop by February 14, 2018.

ADDRESSES: The public workshop will be held at FDA's White Oak Campus, 
10903 New Hampshire Ave., Building 31 Conference Center, the Great Room 
(Rm. 1503), Silver Spring, MD 20993-0002. Entrance for the public 
workshop participants (non-FDA employees) is through Building 1 where 
routine security check procedures will be performed. For parking and 
security information, please refer to https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm. See the SUPPLEMENTARY INFORMATION section for 
registration date and information.
    You may submit comments as follows. Please note that late, untimely 
filed comments will not be considered. Electronic comments must be 
submitted on or before February 14, 2018. The https://www.regulations.gov electronic filing system will accept comments until 
midnight Eastern Time at the end of February 14, 2018. Comments 
received by mail/hand delivery/courier (for written/paper submissions) 
will be considered timely if they are postmarked or the delivery 
service acceptance receipt is on or before that date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2017-N-4790 for ``Self-Collection Devices for Pap Test.'' Received 
comments, those filed in a timely manner (see ADDRESSES), will be 
placed in the docket and, except for those submitted as ``Confidential 
Submissions,'' publicly viewable at https://www.regulations.gov or at 
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through 
Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://

[[Page 42558]]

www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Shyam Kalavar (Rm. 5660, 301-796-6807, 
Shyam.Kalavar@fda.hhs.gov) or Cheng Cui (Rm. 5543, 240-402-5028, 
Cheng.Cui@fda.hhs.gov), Center for Devices and Radiological Health, 
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, 
Silver Spring, MD 20993-0002.

SUPPLEMENTARY INFORMATION:

I. Background

    Cervical cancer is a disease that results from uncontrolled, or 
abnormal, growth of cells in the cervix. Cervical cancer is generally 
considered as a consequence of a long-term infection with human 
papillomavirus (HPV), especially with high-risk strains such as HPV16 
and 18. Through regular screening and early detection, cervical cancer 
can often be prevented. According to the National Cancer Institute, 
routine screening with Pap Test (or Pap smear) and HPV Test in the 
United States has decreased the incidence of cervical cancer, based on 
an estimated 12,820 new cases and 4,210 deaths (0.7 percent of all 
cancer deaths) in 2017 (Ref. 1).
    The standard of care for cervical cancer screening has been well-
established in the United States over the past several decades. 
Automated liquid-based Pap Test has largely replaced conventional Pap 
smear method. Liquid-based cervical specimens can be used for both Pap 
Test and HPV Test. By using specimen collection devices such as a 
cervical broom or cervical spatula and brush combination, cervical 
specimens are collected by healthcare professionals and sent to a 
Clinical Laboratory Improvement Amendments certified laboratory for 
processing for Pap Test and HPV Test. The results of these tests are 
then returned to the ordering clinician who conveys the results to the 
patient and initiates appropriate treatment.
    Despite the established standard of care for cervical cancer 
screening in the United States, gaps in cervical cancer screening 
exist. Barriers to cervical cancer screening may include limited access 
to such services in rural areas, socioeconomic status, etc. As a 
result, in certain populations and geographic areas of the United 
States, cervical cancer incidence and death rate are still high, due in 
large part to limited access to cervical cancer screening (Refs. 2-3).
    The role of self-sampling in overcoming these barriers is unclear. 
Careful evaluation of risks and benefits, and impact to current 
standard of care is needed to better understand issues concerning how 
such devices should be dispensed to end users for self-collection, 
proper use of the device to ensure patient safety, the collection of 
adequate samples for testing, the use of these test results in patient 
care, and the impact on the current regulatory framework. FDA is 
holding this public workshop to solicit input from stakeholders about 
the self-collection of cervical specimens for cancer screening, 
including its feasibility, benefits, risks, current attitudes, and 
impact on current standard of care.

II. Topics for Discussion at the Public Workshop

    This public workshop will consist of both morning and afternoon 
sessions. Each session will include brief presentations followed by an 
interactive panel discussion. The presentations will provide 
information to outline the goals of the workshop and help promote 
interactive discussions. Following the presentations, there will be a 
moderated discussion where speakers and additional panelists will be 
asked to provide their individual perspectives.
    The presentations and discussions will focus on several related 
topics. The morning session will involve scientific considerations, 
focusing on the current status of cervical cancer screening and the 
feasibility, benefits, and risks of self-collection of cervical 
specimens for Pap Test. The afternoon session will involve validation 
and regulatory considerations, focusing on the impact of self-
collection of cervical samples on the current standard of care and the 
regulatory environment for supporting self-collection for Pap Test. A 
detailed agenda will be posted on the following Web site in advance of 
the workshop: https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm.

III. Participating in the Public Workshop

    Registration: To register for the public workshop, please visit 
FDA's Medical Devices News & Events--Workshops & Conferences calendar 
(https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm) and select this event from the list of items provided. 
Please provide complete contact information for each attendee, 
including name, title, affiliation, address, email, and telephone 
number.
    Registration is free and based on space availability, with priority 
given to early registrants. Persons interested in attending this public 
workshop must register by January 3, 2018, 4 p.m. Eastern Time. Early 
registration is recommended because seating is limited; therefore, FDA 
may limit the number of participants from each organization. 
Registrants will receive confirmation when they have been accepted. If 
time and space permit, onsite registration on the day of the public 
workshop will be provided beginning at 8 a.m. We will let registrants 
know if registration closes before the day of the public workshop.
    If you need special accommodations due to a disability, please 
contact Susan Monahan, 301-796-5661 or email Susan.Monahan@fda.hhs.gov, 
no later than December 28, 2017.
    Requests for Oral Presentations: During online registration you may 
indicate if you wish to present during a public comment session or 
participate in a specific session, and which topic(s) you wish to 
address. We will do our best to accommodate requests to make public 
comments. Individuals and organizations with common interests are urged 
to consolidate or coordinate their presentations, and request time for 
a joint presentation, or submit requests for designated representatives 
to participate in the focused sessions. Following the close of 
registration, we will determine the amount of time allotted to each 
presenter and the approximate time each oral presentation is to begin, 
and will select and notify participants prior to the workshop. All 
requests to make oral presentations must be received by the close of 
registration on January 3, 2018, 4 p.m. Eastern Time. If selected for 
presentation, any presentation materials must be emailed to Shyam 
Kalavar and Cheng Cui (see FOR FURTHER INFORMATION CONTACT) in advance 
of the workshop. No commercial or promotional material will be 
permitted to be presented or distributed at the public workshop.
    Streaming webcast of the public workshop: This public workshop will 
also be webcast. The webcast link will be available on the registration 
web page after January 3, 2018. Organizations are requested to register 
all participants, but to view using one connection per location.
    If you have never attended a Connect Pro event before, test your 
connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program, 
visit https://www.adobe.com/

[[Page 42559]]

go/connectpro_overview. FDA has verified the Web site addresses in this 
document, as of the date this document publishes in the Federal 
Register, but Web sites are subject to change over time.
    Transcripts: Please be advised that as soon as a transcript of the 
public workshop is available, it will be accessible at https://www.regulations.gov. It may be viewed at the Dockets Management Staff 
(see ADDRESSES). A link to the transcript will also be available on the 
Internet at https://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm.

IV. References

    The following references are on display in the Dockets Management 
Staff (see ADDRESSES) and are available for viewing by interested 
persons between 9 a.m. and 4 p.m., Monday through Friday; they are also 
available electronically at https://www.regulations.gov. FDA has 
verified the Web site addresses, as of the date this document publishes 
in the Federal Register, but Web sites are subject to change over time.

1. National Cancer Institute, ``Cancer Stat Facts: Cervix Uteri 
Cancer,'' (https://seer.cancer.gov/statfacts/html/cervix.html).
2. Horner, M.J., S.F. Altekruse, Z. Zou, L. Wideroff, et al. ``U.S. 
Geographic Distribution of Pre-Vaccine Era Cervical Cancer 
Screening, Incidence, Stage, and Mortality.'' Cancer Epidemiology, 
Biomarkers & Prevention. 2011 Jan.; 20(4):591-9. doi: 10.1158/1055-
9965. EPI-10-1183.
3. Freeman, H.W.B. ``Excess Cervical Cancer Mortality: A Marker for 
Low Access to Health Care in Poor Communities.'' Rockville (MD): 
National Cancer Institute, Center to Reduce Cancer Health 
Disparities; 2005.

    Dated: September 1, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-19029 Filed 9-7-17; 8:45 am]
BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.